Ivalue Infosolutions Ltd
IVALUEIvalue Infosolutions Ltd is coiled. The quarters are improving, yet the P/E sits at the 16th percentile of its own 1-year range — the business is moving before the market.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (9 weeks in) while the P/E sits at the 16th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +60.0% year on year, and 87% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Ivalue Infosolutions Ltd trades at ₹222, in a confirmed uptrend and 9 weeks into that stage. That is −15.2% against its own 200-day average. It sits at 0% of a 52-week range of ₹222 to ₹312. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a confirmed uptrend — week 9 of stage 2, confirmed. At ₹222 it trades −15.2% versus its 200-day average and sits at 0% of its 52-week range (₹222–₹312).
Against the market, two honest reads. Cumulative: over the last 1.0 years the stock moved −20% while the NIFTY 500 moved +0% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-08-21) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Ivalue Infosolutions Ltd trades at 11.3× P/E, near the bottom of its own range — cheaper only 16% of the time. Its long-run median P/E is 13.2×, measured across 1.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 11.3× is near the bottom of its own range — cheaper only 16% of the time, against a long-run median of 13.2× measured over 1.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved −11.5% against a −19.9% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Ivalue Infosolutions Ltd was paying for profit growth of about 4.5% a year. Profit itself has compounded 23.6% a year over the past 5 years. Today the market pays 11.3× P/E, the 16th percentile of its own 1-year range.
What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 18 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Ivalue Infosolutions Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +14.4% | +9.8% | +2.4% | — |
| Profit | +15.3% | +17.8% | +23.6% | — |
| EPS | −11.5% | −49.8% | −25.9% | — |
| Share price | −19.9% | — | — | — |
4-Factor Sector Score
58.7/100 — rank 11 of 52 in Trading · 65% evidence confidence
Ivalue Infosolutions Ltd scores 58.7 out of 100 against the 52 companies it is compared with in Trading, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20.5 + 18.6 + 11.2 + 8.4 = 58.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Ivalue Infosolutions Ltd reported ₹180 Cr of revenue in the Jun 26 quarter, −21.1% year on year. Over 5 years it has compounded at 2.4% a year. The last full year, FY26, came in at ₹1,056 Cr. The last four reported quarters add to ₹1,008 Cr.
FY26 revenue came in at ₹1,056 Cr (+14.4% on the year), capping 5 years at 2.4% compound. The latest quarter (Jun 26) printed ₹180 Cr, −21.1% year on year.
Pace check: the last four quarters averaged +6.4% growth against the decade's 2.4% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Ivalue Infosolutions Ltd's operating margin is 10.0% in the Jun 26 quarter, +5.6 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 6 fiscal years the operating margin has ranged 5.0% to 13.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 10.0%, +5.6 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged 5.0%–13.0%, and FY26's 13.0% is the top of that band — a record year.
Why the margin moved: operating margin went +5.3 pp year on year while gross margin went +10.9 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Ivalue Infosolutions Ltd earned ₹16.0 Cr of net profit in the Jun 26 quarter, +60.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹98.0 Cr. The 5-year compound rate is 23.6%. That is 8.9% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr.
Jun 26 profit was ₹16.0 Cr, +60.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹98.0 Cr (+15.3%), and the 5-year compound rate is 23.6%.
Why profit moved: revenue contributed −21.1% and the margin +5.6 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +28.8% vs revenue +6.4%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 87% of Ivalue Infosolutions Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹108 Cr of operating cash against ₹98.0 Cr of profit. After ₹0.0 Cr of capital spending, ₹108 Cr was left as free cash.
FY26: operating cash of ₹108 Cr against reported profit of ₹98.0 Cr, leaving free cash of ₹108 Cr after ₹0.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 87% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 87%: the cash cycle tightened 44 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Ivalue Infosolutions Ltd's cash conversion cycle runs −1 days in FY26, down from 43 days in FY21. Capital spending ran ₹13.0 Cr over the last 3 years. At FY26 sales of ₹1,056 Cr each day of that cycle holds about ₹2.9 Cr, so roughly ₹−3.0 Cr sits inside the business at any moment.
FY26: debtors at 336 days, inventory at 3 days — roughly 0.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −1 days, tighter than FY21's 43.
The full loop: cash goes out to suppliers and production on day 0; stock waits 3 days to sell; customers pay about 336 days after that; and suppliers themselves are paid at 341 days — netting out to the −1-day cycle.
In money terms: at FY26 sales of ₹1,056 Cr, each day of the cycle holds about ₹2.9 Cr — so the −1-day loop keeps roughly ₹−3.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹13.0 Cr over the last 3 fiscal years against ₹21.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Ivalue Infosolutions Ltd earns a ROCE of 25% in FY26. Return on invested capital clears the cost of that capital by +16.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 9.3% net margin on 0.73× asset turns.
FY26 ROCE is 25%.
Why the return is what it is — the wiring (FY26): 9.3% net margin × 0.73× asset turns × 2.54× balance-sheet leverage ≈ 17.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 28.2% − 12.0% = a +16.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Ivalue Infosolutions Ltd carries total debt of ₹69.0 Cr against shareholder equity of ₹567 Cr as of Mar 26, a debt-to-equity of 0.12 — effectively unlevered. On the annual view that ratio went from 0.15 in FY25 to 0.12 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹69.0 Cr against shareholder equity of ₹567 Cr — a debt-to-equity of 0.12. On the annual view, debt-to-equity went from 0.15 (FY25) to 0.12 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Ivalue Infosolutions Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Ivalue Infosolutions Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Onix Solar Energy LtdONIXSOLAR | 70.1/100Favorable setup69% evidence | 28.9/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 18.3/25 ROCE 32% · OPM 30% 76% evidence | 10.6/20 P/E 19.9× · PEG — 15% evidence | 12.3/20 RS sector 68.4% · RS bench -21.8% · 1Y 17.8%12 of 12 weeks ahead 70% evidence | |
| Exact sum: 28.9 + 18.3 + 10.6 + 12.3 = 70.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Nupur Recyclers LtdNRL | 68.1/100Favorable setup87% evidence | LEADER | 22.5/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.4/25 ROCE 15.1% · OPM 11.6% 95% evidence | 9.3/20 P/E 57.8× · PEG — 50% evidence | 19.9/20 RS sector 77.1% · RS bench 99.9% · 1Y 99.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 16.4 + 9.3 + 19.9 = 68.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Magnus Steel & Infra Ltd517320 | 67.4/100Thin evidence · provisional56% evidence | 27.7/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.1/20 P/E 92.5× · PEG — 15% evidence | 12.1/20 RS sector — · RS bench 46.1% · 1Y 1449.6%11 of 12 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.7 + 18.5 + 9.1 + 12.1 = 67.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Vision Infra Equipment Solutions LtdVIESL | 67.2/100Thin evidence · provisional56% evidence | BREAKING OUT | 18.9/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.8/25 ROCE 22.6% · OPM 26% 95% evidence | 11.0/20 P/E 14.8× · PEG — 15% evidence | 17.5/20 RS sector 24.6% · RS bench 41.8% · 1Y 104.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 19.8 + 11 + 17.5 = 67.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Rashi Peripherals LtdRPTECH | 63.6/100Mixed-positive evidence75% evidence | LEADER | 24.7/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.5/25 ROCE 17% · OPM 3% 76% evidence | 10.7/20 P/E 16.6× · PEG — 15% evidence | 13.7/20 RS sector 45% · RS bench 61.7% · 1Y 165.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 14.5 + 10.7 + 13.7 = 63.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Shankara Buildpro LtdBUILDPRO | 63.0/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.4/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.3/25 ROCE 39% · OPM 3.2% 100% evidence | 10.3/20 P/E 22.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 12 weeks ahead 0% evidence |
| Exact sum: 25.4 + 17.3 + 10.3 + 10 = 63 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Sudarshan Pharma Industries Ltd543828 | 60.8/100Mixed-positive evidence82% evidence | LEADER | 20.9/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.4/25 ROCE 15.1% · OPM 9.1% 76% evidence | 9.1/20 P/E 39.4× · PEG — 50% evidence | 17.4/20 RS sector 17.6% · RS bench 33.3% · 1Y 28.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 13.4 + 9.1 + 17.4 = 60.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Tembo Global Industries LtdTEMBO | 59.9/100Mixed-positive evidence80% evidence | TURNING | 22.2/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.4/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.2× · PEG — 15% evidence | 8.0/20 RS sector -17% · RS bench -4% · 1Y -6.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 18.4 + 11.3 + 8 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Mangalam Global Enterprise LtdMGEL | 59.5/100Mixed-positive evidence80% evidence | 25.6/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.7/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 7.1/20 RS sector -14.5% · RS bench -0.2% · 1Y -3.4%5 of 6 weeks ahead to 2026-08-09 100% evidence | |
| Exact sum: 25.6 + 15.7 + 11.1 + 7.1 = 59.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Arisinfra Solutions LtdARIS | 58.7/100Mixed-positive evidence65% evidence | BREAKING OUT | 21.9/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 14.9/25 ROCE 15.6% · OPM 11% 95% evidence | 10.8/20 P/E 16.5× · PEG — 15% evidence | 11.1/20 RS sector — · RS bench 5.5% · 1Y -18.2%5 of 10 weeks ahead 25% evidence |
| Exact sum: 21.9 + 14.9 + 10.8 + 11.1 = 58.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Ivalue Infosolutions Ltdthis pageIVALUE | 58.7/100Mixed-positive evidence65% evidence | ASLEEP | 20.5/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.3× · PEG — 15% evidence | 8.4/20 RS sector — · RS bench -13.8% · 1Y -19.9%5 of 10 weeks ahead 25% evidence |
| Exact sum: 20.5 + 18.6 + 11.2 + 8.4 = 58.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Euro Pratik Sales LtdEUROPRATIK | 58.0/100Mixed-positive evidence78% evidence | ASLEEP | 15.0/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.5/25 ROCE 38.4% · OPM 26% 100% evidence | 15.3/20 P/E 27.5× · PEG 0.62 65% evidence | 8.2/20 RS sector — · RS bench -14.6% · 1Y -1.3%5 of 10 weeks ahead 25% evidence |
| Exact sum: 15 + 19.5 + 15.3 + 8.2 = 58 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.7/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.1/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.0/25 ROCE 18.9% · OPM 6% 76% evidence | 8.9/20 P/E 247× · PEG — 15% evidence | 13.7/20 RS sector -0.7% · RS bench 13.9% · 1Y 28.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 13 + 8.9 + 13.7 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Patel Retail LtdPATELRMART | 53.1/100Mixed-positive evidence65% evidence | ASLEEP | 18.0/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.2/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.8/20 P/E 16.5× · PEG — 15% evidence | 10.1/20 RS sector — · RS bench 0.6% · 1Y -20%4 of 10 weeks ahead 25% evidence |
| Exact sum: 18 + 14.2 + 10.8 + 10.1 = 53.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Prostarm Info Systems LtdPROSTARM | 51.6/100Mixed-positive evidence65% evidence | BASING | 17.0/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 15.9/25 ROCE 18% · OPM 8.5% 95% evidence | 10.4/20 P/E 21.4× · PEG — 15% evidence | 8.3/20 RS sector — · RS bench -14% · 1Y -40.8%0 of 10 weeks ahead 25% evidence |
| Exact sum: 17 + 15.9 + 10.4 + 8.3 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Pervasive Commodities Ltd517172 | 50.8/100Thin evidence · provisional52% evidence | TURNING | 16.5/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 14.3/25 ROCE 22.1% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 1 week ahead 0% evidence |
| Exact sum: 16.5 + 14.3 + 10 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Fabtech Technologies LtdFABTECH | 50.7/100Thin evidence · provisional52% evidence | ASLEEP | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.2/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -24.1%0 of 10 weeks ahead 0% evidence |
| Exact sum: 17.5 + 12.2 + 11 + 10 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18BMW Ventures LtdBMW | 49.8/100Thin evidence · provisional55% evidence | 16.9/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 11.7/25 ROCE 12% · OPM 3.4% 76% evidence | 11.2/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead to 2026-08-23 0% evidence | |
| Exact sum: 16.9 + 11.7 + 11.2 + 10 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Bizotic Commercial Ltd543926 | 49.1/100Thin evidence · provisional58% evidence | BASING | 19.7/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.6/25 ROCE 26.8% · OPM 8% 76% evidence | 9.9/20 P/E 37.4× · PEG — 50% evidence | 0.9/20 RS sector -85.3% · RS bench -10.7% · 1Y -74%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 18.6 + 9.9 + 0.9 = 49.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20SG Mart LtdSGMART | 48.8/100Mixed-negative evidence93% evidence | LEADER | 13.9/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.4/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 74.4× · PEG 1.92 65% evidence | 18.3/20 RS sector 30% · RS bench 46.1% · 1Y 104.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 8.4 + 8.2 + 18.3 = 48.8 · Decision use: Price leads the evidence: RS versus the benchmark is 46.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Yogi LtdYOGI | 48.0/100Thin evidence · provisional58% evidence | 20.2/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 9.7/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.5/20 P/E 56.5× · PEG — 15% evidence | 8.6/20 RS sector -6.5% · RS bench -0.3% · 1Y -7.6%2 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.2 + 9.7 + 9.5 + 8.6 = 48 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Shiv Aum Steels LtdSHIVAUM | 47.8/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.8/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.3/25 ROCE 8% · OPM 4.7% 95% evidence | 7.8/20 P/E 67.2× · PEG — 50% evidence | 11.9/20 RS sector — · RS bench 37.8% · 1Y —7 of 7 weeks ahead 25% evidence |
| Exact sum: 16.8 + 11.3 + 7.8 + 11.9 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Lloyds Enterprises LtdLLOYDSENT | 47.7/100Mixed-negative evidence75% evidence | FADING | 18.1/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.0/25 ROCE 3.7% · OPM 16% 76% evidence | 9.2/20 P/E 92.2× · PEG — 15% evidence | 9.4/20 RS sector -6.3% · RS bench 7.2% · 1Y -2.7%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 11 + 9.2 + 9.4 = 47.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Dhunseri Ventures LtdDVL | 47.2/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.5/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.3/25 ROCE 6.7% · OPM 39% 95% evidence | 12.3/20 P/E 5.3× · PEG — 50% evidence | 13.1/20 RS sector -5.2% · RS bench 10.1% · 1Y -17.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.5 + 9.3 + 12.3 + 13.1 = 47.2 · Decision use: Price leads the evidence: RS versus the benchmark is 10.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25State Trading Corporation of India LtdSTCINDIA | 46.7/100Thin evidence · provisional57% evidence | ASLEEP | 22.7/35 Revenue — · PAT 100% · OPM change — 57% evidence | 7.5/25 ROCE 7.6% · OPM — 80% evidence | 10.9/20 P/E 16.1× · PEG — 15% evidence | 5.6/20 RS sector -28.7% · RS bench -6.2% · 1Y -6.3%1 of 11 weeks ahead 70% evidence |
| Exact sum: 22.7 + 7.5 + 10.9 + 5.6 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Adani Enterprises LtdADANIENT | 44.6/100Mixed-negative evidence93% evidence | FADING | 14.3/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.2/25 ROCE 5.8% · OPM 15% 100% evidence | 7.7/20 P/E 172× · PEG 1.96 65% evidence | 14.4/20 RS sector 6.9% · RS bench 21.8% · 1Y 30.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.3 + 8.2 + 7.7 + 14.4 = 44.6 · Decision use: Price leads the evidence: RS versus the benchmark is 21.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 27MMTC LtdMMTC | 42.7/100Mixed-negative evidence96% evidence | ASLEEP | 15.1/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 7.8/25 ROCE 8.7% · OPM — 84% evidence | 15.3/20 P/E 44.9× · PEG 0.92 100% evidence | 4.5/20 RS sector -16.9% · RS bench -4.2% · 1Y -7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 7.8 + 15.3 + 4.5 = 42.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 28Hexa Tradex LtdHEXATRADEX | 42.3/100Mixed-negative evidence65% evidence | BASING | 17.1/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.0/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.2/20 RS sector -15.1% · RS bench -1.9% · 1Y -10.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6 + 10 + 9.2 = 42.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29RRP Semiconductor LtdRRP | 41.1/100Thin evidence · provisional54% evidence | 11.4/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.4/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.3/20 RS sector 65.3% · RS bench 0.8% · 1Y 50.8%0 of 1 week ahead to 2026-08-23 70% evidence | |
| Exact sum: 11.4 + 5.4 + 10 + 14.3 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Cropster Agro Ltd523105 | 40.6/100Mixed-negative evidence65% evidence | 16.0/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence | 11.2/25 ROCE 12.4% · OPM 8.7% 76% evidence | 10.1/20 P/E 31× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -62.7% · 1Y -77.4%0 of 4 weeks ahead to 2026-08-09 70% evidence | |
| Exact sum: 16 + 11.2 + 10.1 + 3.3 = 40.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Hardwyn India LtdHARDWYN | 39.6/100Mixed-negative evidence87% evidence | ASLEEP | 13.6/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.2/25 ROCE 4.8% · OPM 13% 95% evidence | 12.0/20 P/E 50.6× · PEG — 50% evidence | 1.8/20 RS sector -38.2% · RS bench -29.2% · 1Y -4.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 12.2 + 12 + 1.8 = 39.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Blue Pearl Agriventures LtdBPAGRI | 39.5/100Mixed-negative evidence69% evidence | 20.5/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.0/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -90.3%1 of 12 weeks ahead to 2026-08-23 70% evidence | |
| Exact sum: 20.5 + 6 + 8.7 + 4.3 = 39.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Riddhi Siddhi Gluco Biols Ltd524480 | 37.8/100Mixed-negative evidence82% evidence | FADING | 12.4/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.3/25 ROCE 2.7% · OPM -3% 76% evidence | 6.5/20 P/E 37.8× · PEG — 50% evidence | 12.6/20 RS sector 11.6% · RS bench 26.5% · 1Y 35.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 6.3 + 6.5 + 12.6 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34PTC India LtdPTC | 37.1/100Mixed-negative evidence82% evidence | BASING | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.4/25 ROCE 13.4% · OPM 3.1% 76% evidence | 9.4/20 P/E 9× · PEG — 50% evidence | 4.1/20 RS sector -19.7% · RS bench -7.6% · 1Y -10.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.4 + 9.4 + 4.1 = 37.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Neueon Corporation LtdNEUEON | 34.5/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.7/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.7/20 RS sector 12.7% · RS bench -8.1% · 1Y —0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.7 + 10 + 11.7 = 34.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Kothari Industrial Corporation LtdKOTIC | 34.1/100Adverse evidence63% evidence | BASING | 18.7/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.6/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -58.6% · RS bench -37.8% · 1Y -74.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.7 + 1.6 + 10 + 3.8 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Shanti Overseas (India) LtdSHANTI | 32.2/100Thin evidence · provisional56% evidence | 11.2/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.5/25 ROCE -25.2% · OPM -216.5% 71% evidence | 13.0/20 P/E 3× · PEG — 50% evidence | 3.5/20 RS sector -60.4% · RS bench -49.7% · 1Y -47.1%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.2 + 4.5 + 13 + 3.5 = 32.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38BN Agrochem LtdBNAGROCHEM | 31.6/100Adverse evidence77% evidence | BASING | 12.7/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.0/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 119× · PEG — 15% evidence | 5.9/20 RS sector -16.7% · RS bench -30.9% · 1Y -43.5%4 of 11 weeks ahead 70% evidence |
| Exact sum: 12.7 + 4 + 9 + 5.9 = 31.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Uniphos Enterprises LtdUNIENTER | 30.1/100Adverse evidence69% evidence | BASING | 12.4/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.3/25 ROCE 0.8% · OPM — 80% evidence | 8.9/20 P/E 31.1× · PEG — 50% evidence | 4.5/20 RS sector -43.6% · RS bench -21.6% · 1Y -41.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 4.3 + 8.9 + 4.5 = 30.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40Oswal Agro Mills LtdOSWALAGRO | 24.3/100Adverse evidence67% evidence | 2.8/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.5/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.0/20 RS sector -50.3% · RS bench -32% · 1Y -51.4%0 of 5 weeks ahead to 2026-08-16 70% evidence | |
| Exact sum: 2.8 + 7.5 + 10 + 4 = 24.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Proventus Agrocom LtdPROV | 57.0/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.3/25 ROCE 11.5% · OPM 1.8% 95% evidence | 13.1/20 P/E 48.6× · PEG — 50% evidence | 12.0/20 RS sector — · RS bench 42% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.6 + 12.3 + 13.1 + 12 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42DC Infotech & Communication LtdDCI | 56.9/100Thin evidence · provisional35% evidence | 18.5/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.6/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.5/20 P/E 21× · PEG — 15% evidence | 10.3/20 RS sector — · RS bench 1.2% · 1Y — 25% evidence | |
| Exact sum: 18.5 + 17.6 + 10.5 + 10.3 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Mardia Samyoung Capillary Tubes Company LtdMSCTC | 56.9/100Thin evidence · provisional32% evidence | 20.8/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.2/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 74.6% · 1Y 75.6%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.8 + 15.2 + 8.6 + 12.3 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44SK Minerals & Additives Ltd544584 | 55.8/100Thin evidence · provisional36% evidence | BREAKING OUT | 16.6/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.0/25 ROCE 26.2% · OPM 10.7% 76% evidence | 10.2/20 P/E 30.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 5 weeks ahead 0% evidence |
| Exact sum: 16.6 + 19 + 10.2 + 10 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Monika Alcobev LtdMONIKA | 53.8/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 16.9/25 ROCE 21% · OPM 15% 57% evidence | 10.5/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -10.3%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 16.9 + 10.5 + 10 = 53.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Shah Foods Ltd519031 | 53.6/100Thin evidence · provisional18% evidence | BREAKING OUT | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.8/20 P/E 271× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 95.8% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.8 + 12.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Pramara Promotions LtdPRAMARA | 51.8/100Thin evidence · provisional47% evidence | 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence | 13.8/25 ROCE 15.2% · OPM 15% 71% evidence | 6.9/20 P/E 51.3× · PEG — 50% evidence | 14.5/20 RS sector 7.9% · RS bench 29% · 1Y 33.3%10 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 16.6 + 13.8 + 6.9 + 14.5 = 51.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Manbro Industries Ltd512595 | 50.7/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.1/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.3/20 RS sector -17.3% · RS bench 37.2% · 1Y 50.3%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.1 + 10 + 9.3 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49Le Merite Exports LtdLEMERITE | 47.2/100Thin evidence · provisional40% evidence | 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence | 9.0/25 ROCE 8.6% · OPM 2.8% 71% evidence | 9.3/20 P/E 87× · PEG — 15% evidence | 10.0/20 RS sector -9% · RS bench 15% · 1Y 25.1%2 of 12 weeks ahead to 2026-05-17 70% evidence | |
| Exact sum: 18.9 + 9 + 9.3 + 10 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Satani Bearings Ltd505703 | 45.0/100Thin evidence · provisional38% evidence | TURNING | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.4/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5249× · PEG — 15% evidence | 11.5/20 RS sector — · RS bench 24.3% · 1Y 179.3%2 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.4 + 8.6 + 11.5 = 45 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Keto Motors Ltd537392 | 43.0/100Thin evidence · provisional38% evidence | BREAKING OUT | 16.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 5.8/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 6876× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 221.5% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 16.2 + 5.8 + 8.5 + 12.5 = 43 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52A-1 LtdA1L | 40.8/100Thin evidence · provisional50% evidence | 16.1/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.6/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.8/20 P/E 383× · PEG — 15% evidence | 5.3/20 RS sector -24.5% · RS bench -16% · 1Y -9.6%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.1 + 10.6 + 8.8 + 5.3 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Ivalue Infosolutions Ltd's share price today?
Ivalue Infosolutions Ltd trades at ₹222, −19.9% over the past year. The company is valued at ₹1,216 Cr. The stock sits at the very bottom of its 52-week range (₹222–₹312), −15.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 9 weeks in. — as of 18 September 2026.
What were Ivalue Infosolutions Ltd's latest quarterly results?
Ivalue Infosolutions Ltd reported revenue of ₹180 Cr and net profit of ₹16.0 Cr for the Jun 26 quarter. Revenue fell 21.1% and profit rose 60.0% year on year. Earnings per share were ₹2.90. The operating margin was 10.0%, 5.6 pp higher than a year earlier. — as of 18 September 2026.
What is Ivalue Infosolutions Ltd's revenue?
Ivalue Infosolutions Ltd reported revenue of ₹180 Cr in the Jun 26 quarter, −21.1% year on year. For the full FY26 fiscal year, revenue was ₹1,056 Cr (+14.4%). Over the last 5 years revenue compounded at 2.4% a year. — as of 18 September 2026.
What is Ivalue Infosolutions Ltd's profit?
Ivalue Infosolutions Ltd earned ₹16.0 Cr of net profit in the Jun 26 quarter, +60.0% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹98.0 Cr. The operating margin ran 10.0% in the latest quarter. — as of 18 September 2026.
What is Ivalue Infosolutions Ltd's market cap?
Ivalue Infosolutions Ltd's market capitalisation is ₹1,216 Cr at a share price of ₹222. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 18 September 2026.
What is Ivalue Infosolutions Ltd's P/E ratio?
Ivalue Infosolutions Ltd trades at a P/E of 11.3×, at the 16th percentile of its own 1-year range, against a long-run median of 13.2×. This is a comparison with the stock's own history, not a value call — as of 18 September 2026.
Does Ivalue Infosolutions Ltd pay a dividend?
No — Ivalue Infosolutions Ltd has recorded a dividend payout of 0% of profit in each of its last 6 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 18 September 2026.
Is Ivalue Infosolutions Ltd overvalued?
On its own history, Ivalue Infosolutions Ltd looks cheap: its P/E of 11.3× has been cheaper only 16% of the time in 1 years (long-run median 13.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 18 September 2026.
Is Ivalue Infosolutions Ltd growing?
Yes — Ivalue Infosolutions Ltd is growing: latest-quarter revenue −21.1% year on year, profit +60.0%, and the margin +5.6 pp at 10.0%. The 5-year compound rates are 2.4% (revenue) and 23.6% (profit). The earnings engine currently reads: improving — as of 18 September 2026.
How is Ivalue Infosolutions Ltd performing?
Ivalue Infosolutions Ltd is in a confirmed uptrend, 9 weeks in. Its latest quarter's revenue fell 21.1% and profit rose 60.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 18 September 2026.
Is Ivalue Infosolutions Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 9 of stage 2), trading −15.2% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 18 September 2026.
Is Ivalue Infosolutions Ltd beating the market?
Not lately — on a trailing-13-week view Ivalue Infosolutions Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-08-21), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.0 years the stock moved −20% against the NIFTY 500's +0% — behind the index over the full window. — as of 18 September 2026.
Will Ivalue Infosolutions Ltd's share price go up?
This page publishes no price forecast for Ivalue Infosolutions Ltd. What it measures instead: the share price is ₹222, the price is in a confirmed uptrend 9 weeks in. Its P/E of 11.3× sits at the 16th percentile of its own 1-year range. — as of 18 September 2026.
Who owns Ivalue Infosolutions Ltd?
Promoters hold 32.1% of Ivalue Infosolutions Ltd, foreign institutions 2.7%, domestic institutions 15.4% and the public 49.7% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 18 September 2026.
Does Ivalue Infosolutions Ltd have too much debt?
No — Ivalue Infosolutions Ltd's debt-to-equity is 0.12, and operating profit covers the interest bill 11×. FY26 borrowings were ₹69.0 Cr against equity of ₹568 Cr. The returns on this page are earned, not borrowed — as of 18 September 2026.
What is Ivalue Infosolutions Ltd's capex?
Ivalue Infosolutions Ltd spent ₹13.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹0.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 18 September 2026.
What is Ivalue Infosolutions Ltd's cash flow?
Ivalue Infosolutions Ltd generated ₹108 Cr of operating cash flow in FY26 and ₹108 Cr of free cash flow after ₹0.0 Cr of capital spending. Reported profit that year was ₹98.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 18 September 2026.
Is Ivalue Infosolutions Ltd's profit real cash?
Yes — over the last 3 fiscal years, 87% of Ivalue Infosolutions Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹108 Cr against reported profit of ₹98.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 18 September 2026.
Where is Ivalue Infosolutions Ltd in its business cycle?
Ivalue Infosolutions Ltd's FY26 operating margin was 13.0%, against a 6-year band of 5.0%–13.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 10.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 18 September 2026.
What growth does Ivalue Infosolutions Ltd's price assume?
At its price on 13 June 2026, Ivalue Infosolutions Ltd was priced for profit growth of about 4.5% a year. Profit itself has compounded 23.6% a year over the past 5 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 18 September 2026.
What could break the Ivalue Infosolutions Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 18 September 2026.
Is Ivalue Infosolutions Ltd a stock worth studying right now?
This is not investment advice. The machine read: Ivalue Infosolutions Ltd is coiled. The quarters are improving, yet the P/E sits at the 16th percentile of its own 1-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 18 September 2026.
Not SEBI Registered !! Not Investment advice !!